WO2016111276A1 - Promoteur d'absorption de sphingolipides - Google Patents

Promoteur d'absorption de sphingolipides Download PDF

Info

Publication number
WO2016111276A1
WO2016111276A1 PCT/JP2016/050071 JP2016050071W WO2016111276A1 WO 2016111276 A1 WO2016111276 A1 WO 2016111276A1 JP 2016050071 W JP2016050071 W JP 2016050071W WO 2016111276 A1 WO2016111276 A1 WO 2016111276A1
Authority
WO
WIPO (PCT)
Prior art keywords
sphingolipid
sphingomyelin
absorption
lactic acid
milk
Prior art date
Application number
PCT/JP2016/050071
Other languages
English (en)
Japanese (ja)
Inventor
知慧 大庭
雅史 森藤
恵子 河端
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Priority to CN201680004953.2A priority Critical patent/CN107106618B/zh
Priority to SG11201704736QA priority patent/SG11201704736QA/en
Priority to JP2016568379A priority patent/JP6773562B2/ja
Publication of WO2016111276A1 publication Critical patent/WO2016111276A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs

Definitions

  • the present invention relates to a sphingolipid absorption promoter (Absorption Promoter of Sphingolipid).
  • the present invention also relates to a composition for oral ingestion or enteral administration comprising a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria and an additional sphingolipid.
  • Sphingolipid is a component that constitutes eukaryotic cell membranes, and is a generic name for lipids having sphingoid bases. It has been clarified that the effect of improving the barrier function of the skin based on oral ingestion.
  • Sphingomyelin is one of milk-derived sphingolipids.
  • preventive and improving effects on skin conditions decrease in skin barrier function, dryness and roughness of skin, decrease in water content of stratum corneum, atopic dermatitis, etc.
  • ingestion Etc. have been revealed.
  • Sphingomyelin is a substance composed of ceramide and phosphocholine and is hydrolyzed to ceramide and phosphocholine by sphingomyelinase. Furthermore, ceramide is hydrolyzed by ceramidase into sphingoid bases and fatty acids, many of which are absorbed as fatty acids by epithelial cells of the small intestine, and some sphingoid bases are converted into sphingomyelin, ceramide, etc. Recombined. It has been suggested that sphingomyelin is degraded by enteric bacteria.
  • Glucosylceramide is a substance in which glucose is bound to ceramide composed of sphingo base and fatty acid. It is hydrolyzed to ceramide and glucose by glucoceramide-degrading enzyme.
  • Galactosylceramide is a substance in which galactose is bound to ceramide composed of a sphingo base and a fatty acid.
  • lipids when taken orally, they are emulsified by bile acids, decomposed into fatty acids and monoglycerides by lipase, and absorbed in the small intestine. Furthermore, monoglycerides are re-synthesized into triacylglycerol in the epithelial cells of the small intestine, converted into chylomicrons, sent to the lymphatic vessels, pass through the thoracic duct, and then enter the systemic circulation.
  • sphingomyelin and ceramide have low digestibility and absorption. Possible causes include the low activity of sphingomyelinase in the gastrointestinal tract and the elimination of sphingoid bases once absorbed by the transporter expressed there.
  • Patent No. 3920969 proposes a nutritional composition containing bile acids and bile salts in order to improve the digestion and absorption of lipids.
  • sphingolipids it does not describe sphingolipids here, and bile acids themselves are bitter, and their effects must be taken into account when used as food.
  • Fermented milk is a fermented food prepared by mixing lactic acid bacteria and yeast in milk and fermenting it, and is widely eaten from the viewpoint of its deliciousness, beauty and health.
  • Japanese Patent Application Laid-Open No. 7-327633 discloses a chitosan processed food in which chitosan, wheat and wheat yogurt are mixed.
  • powdered yogurt has a function of assisting in digestion and absorption of chitosan.
  • the digestive absorption function here focuses on the action of active lecithin in powdered yogurt, and there is no disclosure or suggestion about the promotion of digestive absorption of sphingolipids.
  • the present inventors have unexpectedly found that when fermented milk (yogurt) is ingested simultaneously with sphingomyelin, the amount of sphingomyelin absorbed can be increased, that is, the absorption of sphingomyelin is improved unexpectedly. I also found. At this time, the present inventors have also found that absorption of ceramide is improved. From these facts, the present inventors have found that absorption of sphingolipids can be promoted by ingestion of fermentation products and / or cultures of lactic acid bacteria and / or bifidobacteria.
  • the skin barrier function expected with the absorption of sphingolipids is improved, and various beneficial effects and effects are improved.
  • the present inventors actually improved the amount of sphingomyelin absorbed into the living body by preparing an oral or enteral composition containing yogurt and sphingomyelin exceeding the yogurt content. confirmed.
  • the present invention is based on these findings.
  • the present invention is a means capable of improving or promoting the absorption of sphingolipids when ingesting sphingolipids, which is safe, simple and economical (or efficient).
  • the purpose is to provide.
  • a sphingolipid absorption promoter comprising as an active ingredient a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria.
  • the sphingolipid is sphingomyelin, and it is preferable to promote absorption of the sphingomyelin into the living body.
  • sphingolipid absorption promoter of ⁇ 2> it is preferable to promote absorption of milk-derived sphingomyelin into the living body.
  • the sphingolipid may be any one or more of ceramide, glucosylceramide, and galactosylceramide.
  • the fermented product and / or culture product of lactic acid bacteria and / or bifidobacteria is a milk fermented product of lactic acid bacteria and / or bifidobacteria and / or Or it may be a milk culture.
  • a sphingolipid absorption promoter comprising a polysaccharide as an active ingredient.
  • a composition for oral ingestion or enteral administration comprising the sphingolipid absorption promoter according to any one of ⁇ 1> to ⁇ 6> above and a sphingolipid.
  • a composition for oral ingestion or enteral administration comprising a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria and an additional sphingolipid.
  • composition for oral ingestion or enteral administration according to ⁇ 7> or ⁇ 8> above, wherein the blending ratio of the lactic acid bacteria and / or bifidobacteria fermented product and / or culture product to the sphingolipid is a sphingolipid.
  • 1 mg of lactic acid bacteria and / or bifidobacteria fermented and / or cultured may be included at 1 to 10,000 mg.
  • the blending ratio of the lactic acid bacteria and / or bifidobacteria fermented product and / or culture product to the sphingolipid is determined as a sphingolipid.
  • 1 mg of lactic acid bacteria and / or bifidobacteria fermented and / or cultured (wet weight) may be included in an amount of 0.01 to 100 g.
  • the sphingolipid may be sphingomyelin.
  • composition for oral intake or enteral administration according to any one of the above ⁇ 7> to ⁇ 11> is used for an in vivo action induced by absorption of sphingomyelin into the living body. Good.
  • the in vivo action of ⁇ 7> is prevention or improvement of skin condition deterioration, cancer suppression action, skin beautification, infant brain It is preferable to be selected from the group consisting of a development promoting action, a mitochondrial function improving action, a motor function improving action, a visceral fat accumulation suppressing action and a blood adiponectin concentration raising promoting action, and an infectious disease preventing action.
  • composition for oral intake or enteral administration according to any one of the above ⁇ 7> to ⁇ 11> may be used for prevention, suppression or improvement of skin condition deterioration.
  • the deterioration of the skin state may be a deterioration of the skin barrier function.
  • a food or drink comprising the sphingolipid absorption promoter of any one of ⁇ 1> to ⁇ 6> or the composition of any one of ⁇ 7> to ⁇ 15>.
  • the food and drink according to ⁇ 16> may be a functional food, a health nutrition food, a supplement, a food for specified health use, a functional display food, or a food with a disease risk reduction display.
  • the sphingolipid may be sphingomyelin.
  • the absorption of sphingomyelin can be improved or promoted, and further, safe, simple and economical (or efficient) sphingomyelin. Can be absorbed.
  • the yogurt used in the absorption enhancer and composition of the present invention has experience in use as a conventional food, so it is highly safe, simple in actual consumption, and economically advantageous. is there.
  • FIG. 5 is a graph showing the results of Example 4 (area under the time curve of the amount of ceramide molecular species in serum) (in the figure, * means that there is a significant difference (P ⁇ 0.05) from the MPL group). , # Means that there is a significant difference (P ⁇ 0.05) with respect to the unfermented milk group).
  • the sphingolipid absorption enhancer of the present invention contains a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria as an active ingredient.
  • active ingredient means that the absorption promoter according to the present invention is used in a sufficient amount (ie, effective amount) of lactic acid bacteria and / or sufficient to exert the action of promoting the absorption of sphingolipids in vivo. It means containing a fermented product and / or culture product of bifidobacteria.
  • “absorption promotion” of sphingolipid means promoting absorption of the sphingolipid into the living body.
  • the term “absorption” as used herein typically refers to a sphingolipid that has been orally or enterally administered simultaneously or sequentially with the absorption enhancer of the present invention, or a sphingolipid that has already been ingested into the body. It is taken up into the circulatory organs (vascular system and lymphatic system) in the living body through the biological membrane in the digestive tract and the absorption tract, etc., so that the actually absorbed sphingolipid is sphingolipid or its induction. As a substance, it is possible to exert various actions on the living body.
  • promotion means that the absorption of sphingolipids is promoted compared to the case where no absorption enhancer is used.
  • the amount of absorption increases and the rate of absorption is increased. Includes improving, improving reduced absorption and the like.
  • promotion is used in the sense of increasing the amount of sphingolipid absorbed into the living body.
  • sphingolipids are naturally derived, such as those derived from milk such as cow's milk, goat milk, sheep milk, and horse milk, those derived from egg yolk, those derived from soybeans, rice, corn, and grains. , Derived from konjac, beet-derived and the like, preferably derived from milk, more preferably derived from milk. Sphingolipids include sphingomyelin, glucosylceramide, and galactosylceramide. The sphingolipid is preferably a sphingophospholipid, more preferably a sphingomyelin. These can be prepared from natural raw materials by a conventional method, but commercially available products may be used.
  • the sphingomyelin that can be used is one of sphingolipids and, like the sphingolipids described above, is naturally derived, preferably milk-derived, more preferably milk-derived. belongs to. Sphingomyelin can be prepared from natural raw materials by a conventional method, but a commercially available product may be used.
  • absorption of milk-derived sphingomyelin into the living body is promoted in the sphingolipid absorption promoter.
  • the absorption of sphingolipid can be evaluated by measuring the amount of sphingolipid into the living body.
  • the absorption of sphingomyelin may be evaluated by paying attention to a certain molecular species of sphingomyelin and measuring the amount of the molecular species taken into the living body.
  • the absorption of sphingomyelin can be evaluated by measuring the amount of a sphingomyelin inducer, for example, ceramide produced by hydrolysis of sphingomyelin, taken into the living body.
  • examples of molecular species contained in sphingomyelin, particularly milk-derived sphingomyelin include the following: That is, it is a sphingomyelin molecular species in which phosphocholine or phosphoethanolamine is bound to a ceramide structure in which sphingosine or dihydrosphingosine having a carbon chain number of 16 to 18 and a fatty acid having a carbon chain of 14 to 26 are amide-bonded respectively.
  • the absorption of sphingomyelin can be evaluated by focusing on one or a combination of a plurality of these molecular species and measuring the amount or the amount of the inducer.
  • sphingomyelin is a substance composed of ceramide and phosphocholine, and is hydrolyzed into ceramide and phosphocholine by sphingomyelinase. Ceramide is further hydrolyzed to sphingoid base and fatty acid by ceramidase.
  • the sphingolipid absorption promoter promotes the absorption of sphingomyelin and also promotes the absorption of ceramide into the living body.
  • absorption of ceramide into the living body is also promoted.
  • an absorption promoter for ceramide, glucosylceramide, and / or galactosylsalamide containing a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria as an active ingredient.
  • a ceramide, glucosylceramide, and / or galactosylsalamide lipid absorption enhancer according to the present invention, absorption of ceramide, glucosylceramide, galactosylsalamide, or a combination of two or more thereof into a living body is also promoted.
  • examples of the molecular species contained in ceramide, glucosylceramide, and galactosylceramide include the following: That is, ceramide molecular species in which sphingosine, dihydrosphingosine, sphingadienin, phytosphingosine or hydroxysphingenin having 16 to 18 carbon chains and amide bonds of fatty acids or hydroxy fatty acids having 14 to 26 carbon chains, respectively.
  • the “fermented product and / or culture of lactic acid bacteria and / or bifidobacteria” means a fermented product of lactic acid bacteria and bifidobacteria, a fermented product of lactic acid bacteria, a fermented product of bifidobacteria, a cultured product of lactic acid bacteria and bifidobacteria, Used to include lactic acid bacteria cultures, bifidobacteria cultures, and combinations thereof.
  • lactic acid bacteria is a general term for microorganisms that assimilate glucose and produce lactic acid with a yield of sugar of 50% or more. It has characteristics such as lack of spore formation and negative catalase. Lactic acid bacteria have been eaten from around the world through fermented milk since ancient times, and can be said to be extremely safe microorganisms. To date, lactic acid bacteria have been classified into 11 genera of Lactococcus, Lactobacillus, Leuconostoc, Pediococcus, Streptococcus, Wissella, Tetragenococcus, Oenococcus, Enterococcus, Vagococcus, and Carnobacterium.
  • Lactobacillus includes, for example, Lactobacillus genus, that is, Lactobacillus eckdelbrueckii subsp. Bulgaricus, Streptococcus thermophilus, Lactobacillus lactis, Lactobacillus gasseri and the like. In particular, it is preferable to use a mixed starter of Lactobacillus delbrueckii subsp. Bulgaricus and Streptococcus thermophilus.
  • Bifidobacterium is a microorganism that assimilates glucose to produce acetic acid and lactic acid, and belongs to the genus Bifidobacterium. Examples include Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium breve and the like.
  • the lactic acid bacteria include a combination of Bulgarian bacteria and thermophilus bacteria, and more preferably a combination of Bulgarian bacteria and thermophilus bacteria.
  • the “fermented product” refers to a culture itself obtained by fermentation with lactic acid bacteria and / or bifidobacteria.
  • “fermented product” refers to a fermented product of lactic acid bacteria and / or bifidobacteria and a processed product thereof, for example, the culture (lactic acid bacteria and / or bifidobacteria fermented product) removed by filtration, centrifugation, membrane separation, or the like.
  • the culture filtrate or culture supernatant obtained by fungi the culture filtrate / culture supernatant, lactic acid bacteria and / or bifidobacteria fermentation product, etc. Heat, reduced pressure, etc.
  • the above-described processing steps such as sterilization treatment such as filtration, centrifugation, and membrane separation, precipitation, concentration, pasting, dilution, and drying are combined. Can be used.
  • examples of the culture medium include nonfat dry milk medium and MRS medium supplemented with yeast extract.
  • the “fermented product and / or culture of lactic acid bacteria and / or bifidobacteria” is a fermented milk and / or milk culture of lactic acid bacteria and / or bifidobacteria.
  • the “fermented product and / or culture product of lactic acid bacteria and / or bifidobacteria” is fermented milk (yogurt).
  • the yogurt may be a supernatant thereof.
  • the “fermented product and / or culture of lactic acid bacteria and / or bifidobacteria” is a polysaccharide.
  • the polysaccharide is preferably derived from a fermentation product and / or a culture product.
  • a sphingolipid absorption promoter comprising a polysaccharide as an active ingredient is provided.
  • milk fermented product and / or milk culture refers to a product obtained by fermenting or culturing a raw material containing milk.
  • milk include animal milk such as cow milk and processed products thereof (eg, skim milk, whole milk powder, skim milk powder, spinach, casein, whey, fresh cream, compound cream, butter, buttermilk powder, etc.) And vegetable milk such as soybean milk derived from soybean.
  • fermented milk raw material mix As a raw material of fermented milk, what is called fermented milk raw material mix is mentioned, for example.
  • the fermented milk raw material mix is a mixture containing raw milk and other ingredients, such as raw milk, water, and other optional ingredients (for example, sugar, sugar, sweetener, acidulant, mineral, vitamin, flavor, etc.) It can obtain by heating, melt
  • Fermented milk can use thickeners and gelling agents such as pectin, guar gum, xanthan gum, carrageenan, and processed starch in culture solutions such as skim milk powder and whey degradation products. Milk includes those before sterilization and those after sterilization.
  • raw milk Specific ingredients (materials) of raw milk include water, raw milk, pasteurized milk, skim milk, whole milk powder, skim milk powder, whole fat concentrated milk, skim concentrated milk, butter milk, butter, cream, etc. Also good. Further, whey protein concentrate (WPC), whey protein isolate (WPI), ⁇ -lactalbumin ( ⁇ -La), ⁇ -lactoglobulin ( ⁇ -Lg) and the like may be included.
  • WPC whey protein concentrate
  • WPI whey protein isolate
  • ⁇ -La ⁇ -lactalbumin
  • ⁇ -Lg ⁇ -lactoglobulin
  • the method for producing fermented milk includes a raw material mix preparation step in which raw materials are mixed (prepared). What is necessary is just to employ
  • a medium usually used can be used as a medium for culturing lactic acid bacteria and the like. That is, any medium can be used as long as it contains a nitrogen source, inorganic substances and other nutrients in addition to the main carbon source.
  • the carbon source lactose, glucose, sucrose, fructose, starch hydrolyzate, waste molasses and the like can be used according to the assimilation ability of the bacteria used.
  • the nitrogen source organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, ⁇ -lactalbumin, ⁇ -lactoglobulin, glycomacropeptide, and soy protein hydrolyzate can be used.
  • the growth promoter meat extract, fish extract, yeast extract and the like can be used as the growth promoter.
  • an anaerobic state is preferable, but a microaerobic state by liquid stationary culture ordinarily used may be used.
  • a known method such as a method of culturing in a carbon gas gas layer can be applied, but other methods may be used.
  • the culture temperature is preferably 30 to 47 ° C, more preferably 35 to 46 ° C, and still more preferably 37 ° C to 45 ° C.
  • the pH of the medium in which lactic acid bacteria and the like are cultured is preferably maintained at 6 to 7, but other pH conditions may be used as long as the temperature allows the bacteria to grow.
  • the culture time for lactic acid bacteria and the like is usually preferably 1 to 48 hours, more preferably 8 to 36 hours, still more preferably 10 to 24 hours.
  • the solid content of non-fat milk is 8% by weight or more, and the number of lactic acid bacteria or the number of yeasts is 10 million / ml or more. For example, it is 10 11 pieces / ml or less.
  • the fermented product and / or culture of lactic acid bacteria and / or bifidobacteria which are active ingredients of the present invention, have sphingolipid absorption promoting activity (Examples 1 and 2 to be described later), and usually ceramide absorption promoting activity. Also have. Therefore, the use of the sphingolipid absorption promoter of the present invention can improve the absorption of the sphingolipid in the living body, and thus various effects exhibited by the presence of the sphingolipid or its derivative in the living body. Can be further improved.
  • sphingolipid is sphingomyelin
  • sphingomyelin absorption promoter of the present invention it is possible to improve the absorption of sphingomyelin in vivo, Various actions exhibited by the presence of sphingomyelin or a derivative thereof in a living body can be further improved.
  • the sphingolipid is ceramide, glycosyl ceramide, or galactosyl ceramide
  • the ceramide, glycosyl ceramide, or galactosyl ceramide absorption enhancer of the present invention by using the ceramide, glycosyl ceramide, or galactosyl ceramide absorption enhancer of the present invention, in vivo ceramide, glycosyl ceramide, or Absorption of galactosylceramide can be improved. For this reason, various actions exhibited by the presence of ceramide, glycosylceramide, or galactosylceramide and their derivatives in vivo can be further improved.
  • Deterioration of skin condition due to increased presence of sphingomyelin or its inducer in the body (decreased skin barrier function, dry skin and skin, decreased moisture content of stratum corneum, atopic dermatitis, etc. ) Can be improved, improved, enhanced, and improved in preventive effect.
  • visceral fat accumulation suppression and blood adiponectin concentration increase promoting action (anti-hyperglycemic action, anti-hyperlipidemic action) (JP 2007) -320900), infectious disease prevention action (Japanese Patent Laid-Open No. 2008-037788), and the like.
  • the skin barrier function can be further improved in the state where the skin barrier function is lowered by ultraviolet rays.
  • the deterioration of the skin condition includes, for example, a reduction in skin barrier function, skin drying, skin roughness, a decrease in the amount of water in the stratum corneum, and atopic dermatitis.
  • Reduction of the barrier function of the skin includes maintenance of the barrier function.
  • the reduction in the skin barrier function is preferably a reduction in the skin barrier function under the irradiation of ultraviolet rays.
  • prevention, suppression or improvement of an exacerbated state is used in a sense encompassing adjustment, delay of progression, mitigation, prevention of onset, prevention of recurrence, etc. of such a state.
  • the present invention it is possible to increase the amount of sphingolipid absorbed in the living body by promoting the absorption of the sphingolipid, and as a result, the in vivo action (function) induced by the absorption of the sphingolipid into the living body. , Efficacy) can be improved, improved and enhanced.
  • the in vivo action referred to here is induced by absorption of sphingolipid into the living body, and specifically has various effects as described above. Therefore, according to the present invention, it is also possible to provide an enhancer of an action (function) in vivo induced by absorption of sphingolipid (an enhancer of function accompanying absorption (ingestion) of sphingolipid).
  • composition for Oral Intake or Enteral Administration As described above, according to the present invention, the active ingredient of the present invention, that is, a fermented and / or cultured product of lactic acid bacteria and / or bifidobacteria, and a sphingolipid.
  • a composition for oral ingestion or enteral administration is provided. It can also be said that this composition comprises the sphingolipid absorption promoter of the present invention as such an active ingredient.
  • Lactic acid bacteria and / or bifidobacteria fermentations and / or cultures often already contain sphingolipids themselves, but in a preferred embodiment of the invention the composition of the invention comprises lactic acid bacteria and And / or bifidobacteria fermentation and / or culture and additional sphingolipids.
  • the composition of the present invention can be distinguished from a fermentation product and / or culture product of lactic acid bacteria and / or bifidobacteria such as conventional yogurt.
  • additional sphingolipid refers to a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria when a sphingolipid is contained in the fermented product and / or culture of lactic acid bacteria and / or bifidobacteria. It means a sphingolipid that is additionally present in the composition beyond the amount of the sphingolipid itself contained in the product.
  • the sphingolipid itself may be used as it is, and examples thereof include a high content phospholipid concentrate (MPL) of milk-derived sphingomyelin. It can also be obtained as an insoluble fraction of acetone (solvent) and / or ethanol from cream or butter or from butter ram which is a by-product in producing butter oil.
  • MPL high content phospholipid concentrate
  • Bataselam is also used in the city milk field and is available (for example, manufactured by Tatua, New Zealand). Bataselam is rich in MFGM in which sphingomyelin is localized, and is suitable as a raw material.
  • the total lipid was extracted from chicken skin powder, and the dried total lipid was dried and extracted with a mixed solvent of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent, and an insoluble portion mainly composed of sphingomyelin was removed.
  • a method for extracting sphingomyelin by extraction with a mixed solvent of water and a water-soluble ketone solvent and removing non-lipid components contained in the soluble part Existing methods such as extraction methods from seafood and animal birds can be used. From the viewpoint of flavor, milk-derived sphingomyelin is preferred.
  • fermented products and / or cultures of lactic acid bacteria and / or bifidobacteria are set type yogurt (solid fermented milk), soft type yogurt (pasted fermented milk), drink yogurt (liquid fermented milk).
  • Various forms of yogurt such as cereals, fruits, vegetables, and nutrient ingredients may also be used.
  • composition for oral ingestion or enteral administration of the present invention is preferably one in which the absorption of sphingolipids into the living body is enhanced, more preferably the absorption of sphingomyelin into the living body is enhanced. It is a thing. That is, the composition for oral ingestion or enteral administration of the present invention can be referred to as a “sphingolipid superabsorbent”, preferably a “sphingomyelin superabsorbent” composition for oral ingestion or enteral administration.
  • a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria, and sphingo is preferably 1 to 10000 mg, more preferably 5 to 5000 mg of lactic acid bacteria and / or bifidobacteria fermentation and / or culture (dry weight (powder)) per 1 mg of sphingolipid. More preferably, it is contained in an amount of 10 to 750 mg.
  • the fermented product and / or culture of lactic acid bacteria and / or bifidobacteria in the composition for oral consumption or enteral administration of the present invention And the ratio of sphingolipid to 1 mg of sphingolipid, preferably 0.01 to 100 g, more preferably 0.05 to lactic acid bacteria and / or bifidobacteria fermented product and / or culture (wet weight). To 50 g, more preferably 0.1 to 7.5 g.
  • composition for oral ingestion or enteral administration of the present invention is preferably used for in vivo action induced by absorption of sphingomyelin into the living body.
  • the composition for oral ingestion or enteral administration according to the present invention is more preferably such that the action in the living body is prevention or improvement of skin condition deterioration, cancer suppression action, skin beautification, infant brain development promotion. It is used for an action selected from the group consisting of an action, an action to improve mitochondrial function, an action to improve motor function, an action to suppress visceral fat accumulation and an increase in blood adiponectin concentration, and an action to prevent infection.
  • the composition for oral intake or enteral administration of the present invention is preferably used for preventing, suppressing or improving the deterioration of the skin condition.
  • the deterioration of the skin condition is preferably a deterioration of the barrier function of the skin.
  • the deterioration of the barrier function of the skin is due to the irradiation of ultraviolet rays.
  • the composition of this invention can be a pharmaceutical composition as one preferable aspect.
  • the pharmaceutical composition is prepared as an oral preparation or a parenteral preparation according to a conventional method using additives that are acceptable for formulation. From the viewpoint of simplicity, an oral preparation is preferable.
  • oral preparations take the form of solid preparations such as tablets, powders, fine granules, granules, capsules, pills, sustained-release preparations, and liquid preparations such as solutions, suspensions, and emulsions. Can do.
  • Additives that are acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, colorants, fragrances, buffers, antioxidants, pH Examples thereof include regulators.
  • a food or drink comprising the sphingolipid absorption promoter of the present invention or the composition for oral intake or enteral administration described above.
  • compositions and food / beverage products of this invention are manufactured by the manufacturing method which comprises adding the absorption promoter of this invention, or its active ingredient to the composition and the material component of food / beverage products, for example. Can do.
  • Arbitrary ingredients can be added to the food and drink of the present invention as required.
  • optional components that can be added there are no particular restrictions, but usually ingredients to be blended in foods and drinks, sweeteners, acidulants, vegetable and fruit juices and their extracts, vitamins, minerals, Nutrients such as amino acids, useful microorganisms such as lactic acid bacteria, bifidobacteria and propionic acid bacteria and their cultures, functional sugars such as oligosaccharides, royal jelly, collagen, ceramide, glucosamine, astaxanthin and polyphenols
  • filler, a sour agent, a coloring agent, an emulsifier, a preservative, etc. can be mix
  • the food and drink are other than the pharmaceutical composition and are not particularly limited as long as they are ingestible forms such as solutions, suspensions, emulsions, powders, and solid molded products.
  • dairy products such as milk drinks, yogurts, lactic acid bacteria drinks, fermented milk, ice creams, creams, cheeses; soft drinks, fruit juice drinks, vegetable drinks, soy milk drinks, coffee drinks, tea drinks Jelly drinks, cocoa, smoothie powdered drinks and sports powdered drinks, nutrition-enriched powdered drinks, cosmetic powdered foods, powdered soup, steamed bread, concentrated drinks, alcoholic drinks, etc .
  • bread, pasta , Flour products such as noodles, cake mix, fried flour, bread crumbs
  • confectionery such as chocolate, gum, candy, cookies, gummi, snacks, Japanese confectionery, jelly, pudding, etc .
  • the food and drink are milk drinks (which may include processed milk), fermented milk, soft drinks, jelly drinks, tablets, cosmetic powdered foods, powdered drinks, liquid foods, liquids.
  • the food and drink is a milk beverage, fermented milk, soft drink, jelly beverage, prepared milk powder tablet, cosmetic powdered food, and according to a more preferred embodiment, the food and drink The product is a milk beverage (which may include processed milk), fermented milk.
  • the food or drink is a functional food, a health nutrition food, a supplement, a food for specified health use, a functional display food, or a food with a disease risk reduction display.
  • the indication of disease risk reduction is the indication of food and drink that may reduce the disease risk, and is based on the standards established by the FAO / WHO Joint Food Standards Committee (Codex Committee). , Or with reference to the standard, it can be a defined or recognized display.
  • the food and drink of the present invention are, for example, foods suitable for consumers who expect improvement or alleviation of skin condition deterioration, foods suitable for improvement of skin condition deterioration, that is, so-called foods for specific health use or functions It can be provided as a sex indication food.
  • the content of sphingomyelin in the food and drink and the composition within a predetermined range.
  • the specific content can be changed depending on the type and form of the food or drink or the composition, the purpose of prevention / improvement, etc., and thus it is difficult to define it uniformly, but in the composition of the present invention, the adult ( (Weight: 60 kg) per day, milk-derived sphingomyelin can be adjusted to an effective amount that can be ingested at 0.5 to 1500 mg, preferably 1 to 1000 mg, more preferably 5 to 500 mg.
  • the content of sphingolipid for example, sphingomyelin, can be measured by a conventional method, but may be measured, for example, according to the description in Examples 1 and 2 described later. Moreover, for example, it can measure using liquid chromatography and using AQUASIL SP100 (4.6X250mm, Senshu Scientific Co., Ltd.) as a column.
  • the mobile phase for example, a solution in which 0.5 mM phosphate-citrate buffer (pH: 3.0) and methanol are mixed at a ratio of 5 to 95 may be used.
  • the measurement time can be set to 20 minutes
  • the flow rate of the mobile phase can be set to 0.6 mL / min
  • the column temperature can be set to 40 ° C.
  • the absorbance can be detected at 205 nm.
  • sphingomyelin derived from milk, Nagara Science Co., Ltd.
  • it can be quantified by the area ratio.
  • the content of the active ingredient in foods and drinks and compositions can be defined per packaging form.
  • the content of sphingolipids is preferably 5 to 1500 mg. 6 to 1000 mg, more preferably 7 to 500 mg, and in the case of a composition, the content of sphingolipid is 0.5 to 1500 mg, preferably 1 to 1000 mg, more preferably 5 to 500 mg. be able to.
  • the amount (content) per packaging form is not limited to a single intake, and may include intakes for multiple doses or multiple days (for example, for 30 days).
  • the content of sphingolipid is 5 to 45000 mg, preferably 6 to 30000 mg, more preferably 7 to 15000 mg.
  • the content of sphingolipid is 0.5 to 45000 mg, preferably 1 It can be contained in an amount of ⁇ 30000 mg, more preferably 5 to 15000 mg.
  • the conventional general milk drink and fermented milk contain 20 mg of phospholipid per gram of lipid, whereas the milk drink and fermented milk of the present invention contain 25 to 3000 mg of phospholipid per gram of lipid. , Preferably 30 to 2500 mg, more preferably 40 to 2000 mg, and still more preferably 50 to 1500 mg.
  • the conventional general milk drink and fermented milk contain 6 mg of sphingomyelin per gram of lipid, but the food or drink or composition of the present invention contains 7 to 1500 mg of sphingomyelin per gram of lipid. Contained, preferably 8 to 1250 mg, more preferably 9 to 1000 mg, and still more preferably 10 to 750 mg. That is, in one preferred embodiment of the present invention, those having an intentionally increased sphingomyelin content are used.
  • phospholipid is contained at 1 to 300 mg / g, preferably 1.5 to 250 mg / g. More preferably 2 to 200 mg / g, still more preferably 2.5 to 150 mg / g.
  • sphingomyelin is contained at 0.2 to 60 mg / g, preferably 0.25 to 50 mg / g, more preferably 0.3. It can be contained at -40 mg / g, more preferably 0.35-30 mg / g.
  • the conventional general milk drink and fermented milk contain 20 mg of phospholipid per gram of lipid, but the milk drink and fermented milk of the present invention contain 25 to 3000 mg of phospholipid per 1 g of lipid. It is preferably contained in an amount of 30 to 2500 mg, more preferably 40 to 2000 mg, and still more preferably 50 to 1500 mg.
  • sphingomyelin is contained at 0.05 to 60 mg / g, preferably 0.1 to 50 mg / g, more preferably 0.15 to It can be contained at 40 mg / g, more preferably 0.2 to 30 mg / g.
  • the conventional general milk drink and fermented milk contain 20 mg of phospholipid per gram of lipid, but the milk drink and fermented milk of the present invention contain 25 to 3000 mg of phospholipid per 1 g of lipid. It is preferably contained in an amount of 30 to 2500 mg, more preferably 40 to 2000 mg, and still more preferably 50 to 1500 mg.
  • sphingomyelin when containing almost no lipid (non-fat), is contained at 0.02 to 60 mg / g.
  • it can be contained at 0.04 to 50 mg / g, more preferably 0.06 to 40 mg / g, and still more preferably 0.08 to 30 mg / g.
  • a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria is orally administered or enterally administered to a subject who wants to take the sphingolipid simultaneously with the sphingolipid.
  • a method for promoting the absorption of sphingolipids is preferably, the sphingolipid is sphingomyelin.
  • a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria is orally administered or enterally administered to a subject who wants to take sphingolipids simultaneously with sphingolipids.
  • a method for promoting absorption of ceramide is provided.
  • the above method excludes medical use.
  • the subject is preferably a human or a non-human mammal.
  • the method is preferably used for a subject in whom intake of sphingolipid is desired, wherein a fermented product and / or culture of lactic acid bacteria and / or bifidobacteria are continuously orally ingested for 2 days or more, or enterally administered. Therefore, it is possible to provide a method for promoting absorption of sphingolipids and a method for promoting absorption of ceramides for subjects in whom intake of sphingolipids is desired.
  • Example 1 Evaluation test of absorbability of sphingomyelin in simultaneous administration of yogurt and sphingomyelin To rats, only milk-derived sphingomyelin is administered, or powdered yogurt and milk-derived sphingomyelin are administered simultaneously, lymph The amount of sphingomyelin absorbed was evaluated.
  • test solution (A), (B) and (C) as will be described later, the rats are divided into 3 groups (a, b, c), and these test solutions are administered into the stomach. From 1 hour before, lymph fluid was collected in Spitz tubes treated with EDTA for 3 groups (a, b, c).
  • each test solution (A), (B), and (C) was sent into the stomach in 1 minute using a syringe pump (flow rate: 3 mL / min), and then the syringe pump was used.
  • the buffer solution was fed into the stomach in 6 hours (flow rate: 3 mL / min).
  • lymph fluid was collected in Spitz tubes treated with EDTA for three groups (a, b, c).
  • Test Solution Each test solution (A), (B) and (C) was prepared as follows.
  • Triolein 195 mg, bovine serum albumin: 50 mg, and sodium taurocholate: 200 mg were mixed with milk-derived sphingomyelin (SM, purity 98%, Nagara Science Co., Ltd.): 5 mg ultrasonically emulsified. It was.
  • SM milk-derived sphingomyelin
  • Triolein 192 mg, bovine serum albumin: 50 mg, and sodium taurocholate 200 mg were mixed with milk-derived sphingomyelin (SM, purity 98%, Nagara Science): 4.75 mg was emulsified with ultrasound. I let you. Along with this, 250 mg of powdered yogurt (YG, fat: about 0%, Meiji Bulgaria yogurt fat, obtained from Meiji Co., Ltd.) was prepared.
  • SM milk-derived sphingomyelin
  • ceramide (d18: 1-C16: 0, obtained from Avanti Polar Lipids) and sphingomyelin (d18: 1-C16: 0 SM, obtained from Avanti Polar Lipids) were used. Using these standard products as equivalents, ceramide (d16: 1-C16: 0), sphingomyelin (d16: 1-C16: 0 SM) using LC / MS / MS (ACQUITY premier XE (Waters)) was quantified.
  • mobile phase A was started from 100%, and after 30 minutes, mobile phase B was gradiented to 100%, then mobile phase B was made 100% and held for 2 minutes, and after another 3 minutes, The mobile phase A was switched to 100%.
  • the measurement time of one sample in LC / MS / MS is set to 35 minutes
  • the flow rate of the mobile phase is set to 0.4 mL / min
  • the temperature of the column is set to 40 ° C.
  • electrospray ionization is used. Detected with.
  • capillary voltage is 3000V
  • source temperature is 120 ° C
  • solvent removal temperature is 400 ° C
  • solvent removal gas flow rate is 850L / hour
  • cone gas flow rate is 50L / hour
  • cone The voltage was set at 40V / hour.
  • FIG. 1 shows the transition of the amount of ceramide molecular species (d16: 1-C16: 0).
  • the ceramide molecular species amount was higher in the SM + YG group than in the SM group.
  • FIG. 2 shows changes in the amount of sphingomyelin molecular species (d16: 1-C16: 0 SM).
  • 3, 4, 5, and 6 hours after oral administration of each test solution the amount of sphingomyelin molecular species was higher in the SM + YG group than in the SM group.
  • Example 2 Evaluation test of absorbability of sphingomyelin in simultaneous intake of yogurt and milk-derived sphingomyelin-rich phospholipid concentrate (MPL) Oral administration of MPL alone or oral administration of yogurt and MPL simultaneously to rats Thus, the amount of ceramide in the blood was evaluated.
  • MPL milk-derived sphingomyelin-rich phospholipid concentrate
  • MPL Group Test Solution
  • D MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
  • E MPL + YG group: Test solution
  • E Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight was administered.
  • ceramide (d18: 1-C16: 0, d18: 1-C22: 0, d18: 1-C23: 0, d18: 1-C24: 0, obtained from Avanti Polar Lipids) was used. Using these standard products as equivalents, LC / MS / MS (ACQUITY premier XE (manufactured by Waters)) was used and ceramide (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0).
  • mobile phase A was started from 100%, and after 30 minutes, mobile phase B was gradiented to 100%, then mobile phase B was made 100% and held for 2 minutes, and after another 3 minutes, The mobile phase A was switched to 100%.
  • the measurement time of one sample in LC / MS / MS is set to 35 minutes
  • the flow rate of the mobile phase is set to 0.4 mL / min
  • the temperature of the column is set to 40 ° C.
  • electrospray ionization is used. Detected with.
  • capillary voltage is 3000V
  • source temperature is 120 ° C
  • solvent removal temperature is 400 ° C
  • solvent removal gas flow rate is 850L / hour
  • cone gas flow rate is 50L / hour
  • cone The voltage was set at 40V / hour.
  • FIG. 3 shows changes in serum ceramide molecular species (d16: 1-C16: 0, d16: 1-C22: 0, d16: 1-C23: 0, d16: 1-C24: 0).
  • ceramide molecular species (d16: 1-C16: 0) 90 and 180 minutes after administration of the test solution, and for ceramide molecular species (d16: 1-C22: 0, d16: 1-C23: 0), At 90, 180, and 270 minutes after administration, ceramide molecular species (d16: 1-C24: 0) were significantly more significant in the MPL + YG group than in the MLP group at 90, 180, 270, and 360 minutes after administration of the test solution. It was overpriced.
  • FIG. 4 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species were significantly higher in the MPL + YG group in the area under the time curve than in the MPL group.
  • Example 3 Effect of yogurt and sphingolipid on deterioration of skin barrier function under irradiation of ultraviolet rays
  • Hairless mice whose skin barrier function was deteriorated by irradiation with ultraviolet rays were treated with sphingomyelin or sphingomyelin and yogurt. It was orally ingested for 3 days, and the influence on the skin barrier function (the amount of stratum corneum moisture, the amount of transdermal moisture transpiration (TEWL)) was evaluated.
  • sphingolipid milk-derived sphingomyelin (SM, purity 98%, Nagara Science) was used.
  • Control group group in which normal feed is ingested
  • SM group group in which sphingomyelin is orally administered at 10 mg / kg / day
  • SM + YG group sphingomyelin and yoghurt in 10 mg / kg / day, 11.3 g / kg /
  • a group to be orally administered on day (however, in the SM group and SM + YG group, collagen is further orally administered at a rate of 1000 mg / kg / day in addition to sphingomyelin and yogurt).
  • Transdermal moisture transpiration (TEWL) Transcutaneous moisture transpiration (TEWL) was measured with a tevameter (Tewemeter MPA580, Curage and Khazaka Electronic GmbH) using a probe kept at 29 ° C. for 20 seconds. About the obtained measurement result, the average of 3 times was employ
  • TEWL Transdermal moisture transpiration
  • Example 4 Evaluation test of absorption of sphingomyelin in simultaneous intake of unfermented milk and MPL When rats were orally administered with MPL alone, when yogurt and MPL were orally administered simultaneously, and with unfermented milk and MPL The amount of ceramide in the blood was evaluated for each case of simultaneous oral administration.
  • Rats SD strain, male, body weight: about 270 g
  • test solutions F), (G) and (H) shown below were orally administered.
  • blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.
  • MPL group Test solution (F): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
  • MPL + YG group Test solution (G): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight was administered.
  • FIG. 7 shows the area under the time curve of the amount of ceramide molecular species in serum.
  • the area under the time curve was significantly higher in the order of the MPL group, the MPL + unfermented milk group, and the MPL + YG group in comparison with the MPL group.
  • Absorption of sphingomyelin is promoted by simultaneous ingestion of milk-derived phospholipid concentrate and non-fermented milk at a high content of sphingomyelin, but milk-derived phospholipid concentrate at a high content of sphingomyelin It was found that the simultaneous intake of yogurt and yogurt further promotes the absorption of sphingomyelin.
  • Example 5 Evaluation test of absorption of sphingomyelin in simultaneous intake of yogurt fraction and MPL When rats were orally administered with MPL alone, yogurt and MPL were orally administered simultaneously, yogurt fraction supernatant and The amount of ceramide in blood was evaluated when MPL was orally administered at the same time and when yogurt fraction precipitate and MPL were orally administered at the same time.
  • Rats SD strain, male, body weight: about 270 g
  • test solutions I), (J), (K) and (L) shown below were orally administered.
  • blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.
  • MPL Group Test Solution (I): MPL: 540 mg (100 mg as sphingomyelin) was administered per 1 kg of body weight.
  • MPL + YG group Test solution (J): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight Was administered.
  • K MPL + YG supernatant group: Test solution (J): Yogurt supernatant: 743 mg and MPL: 539 mg (100 mg as the total amount of sphingomyelin) were administered per kg of body weight.
  • MPL + YG precipitation group Test solution (K): Yogurt precipitation: 455 mg and MPL: 536 mg (100 mg as the total amount of sphingomyelin) were administered per 1 kg of body weight.
  • FIG. 8 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species had significantly higher areas under the time curve in the MPL + YG group and MPL + YG supernatant group than in the MPL group, but there was a significant difference between the MPL group and the MPL + YG precipitation group. There wasn't.
  • Example 6 Evaluation test of absorption of sphingomyelin in simultaneous intake of lactic acid and MPL When MPL alone was orally administered to rats, yogurt and MPL were orally administered simultaneously, and lactic acid and MPL were orally administered simultaneously For each of these, the amount of ceramide in the blood was evaluated.
  • Rats SD strain, male, body weight: about 270 g
  • test solutions L), (M) and (N) shown below were orally administered.
  • blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.
  • MPL Group Test solution (L): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
  • MPL + YG group Test solution (M): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight was administered.
  • N MPL + lactic acid group: Test solution (N): Lactic acid (obtained from Wako Pure Chemical Industries, Ltd.) per kg of body weight: 109 mg (the amount of lactic acid in yogurt was equal to the pH), and MPL: 540 mg (sphingo A dose of 100 mg) was administered as myelin.
  • FIG. 9 shows the area under the time curve of the amount of ceramide molecular species in serum.
  • the area under the time curve was significantly higher in the MPL + YG group than in the MPL group, but no significant difference was observed between the MPL group and the MPL + lactic acid group.
  • Example 7 Evaluation test of absorption of sphingomyelin in simultaneous intake of whey protein and MPL When rats were orally administered MPL alone, yogurt and MPL were orally administered simultaneously, and whey protein and MPL were orally administered simultaneously In each case, the amount of ceramide in the blood was evaluated.
  • Rats SD strain, male, body weight: about 270 g
  • test solutions O), (P) and (Q) shown below were orally administered.
  • blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after administration, and serum was obtained according to a conventional method.
  • MPL Group Test Solution
  • O MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
  • MPL + YG group Test solution
  • P Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as total amount of sphingomyelin) per kg of body weight was administered.
  • FIG. 10 shows the area under the time curve of the amount of ceramide molecular species in serum.
  • the area under the time curve was significantly higher in the MPL + YG group than in the MPL group, but there was no significant difference between the MPL group and the MPL + whey protein group.
  • Example 8 Evaluation Test of Sphingomyelin Absorption by Simultaneous Intake of Polysaccharide and MPL When rats are orally administered with MPL alone, yogurt and MPL are orally administered simultaneously, and polysaccharide and MPL are orally administered simultaneously In each case, the amount of ceramide in the blood was evaluated.
  • Rats SD strain, male, body weight: about 270 g
  • Rats were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, they were divided into 3 groups, and the test solutions (R), (S) and (T) shown below were orally administered. Subsequently, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a conventional method.
  • MPL group Test solution (R): MPL: 540 mg (100 mg as sphingomyelin) was administered per kg of body weight.
  • S MPL + YG group: Test solution (S): Dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg as the total amount of sphingomyelin) per kg of body weight was administered.
  • T MPL + polysaccharide group: Test solution (T): administration of polysaccharide: 52.5 mg (equal to polysaccharide in yogurt) and MPL: 540 mg (100 mg as sphingomyelin) per kg body weight did.
  • FIG. 11 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species were significantly higher in the area under the time curve in the MPL + YG group and the MPL + polysaccharide group than in the MPL group.
  • Example 9 Evaluation test of absorption of sphingomyelin in simultaneous intake of yogurt and MPL prepared by lactic acid bacteria and / or bifidobacteria When MPL alone was orally administered to rats, it was prepared by lactic acid bacteria and / or bifidobacteria The amount of ceramide in blood was evaluated for each of the cases where yogurt and MPL were orally administered simultaneously.
  • Rats SD strain, male, body weight: about 270 g
  • Rats were acclimated and bred in one week. Then, after the rats were fasted for 16 hours, the rats were divided into 3 groups, and the test solutions (U), (V), (W), (X) and (Y) shown below were orally administered. Subsequently, blood was collected from the tail vein at each timing before administration, 90 minutes, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a conventional method.
  • MPL Group Test Solution (U): MPL: 540 mg (100 mg as sphingomyelin) was administered per 1 kg of body weight.
  • V MPL + YG (1) group: Test solution (V): Yogurt per kg of body weight (1) (prepared by lactic acid bacteria Lactobacillus Gasseri and Streptococcus thermophilus, Meiji Probio Yogurt LG21 Fat Zero, obtained from Meiji Co., Ltd.): A dose of 3 g and MPL: 535 mg (100 mg as the total amount of sphingomyelin) was administered.
  • (Y) MPL + YG (4) group Test solution (Y): Yogurt per kg of body weight (4) (prepared by Bifidobacterium longum, bihidas BB536 plain yogurt fat zero, obtained from Morinaga Milk Industry Co., Ltd.): 11.3 g , And MPL: 535 mg (100 mg total sphingomyelin) was administered.
  • FIG. 12 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species had significantly higher areas in the MPL + YG (1) group, the MPL + YG (2) group, the MPL + YG (3) group, and the MPL + YG (4) group as compared to the MPL group.
  • Example 10 Evaluation test of absorption of glucosylceramide in simultaneous intake of yogurt and glucosylceramide When glucosylceramide (GC) alone was orally administered to a rat, each of cases where yogurt and glucosylceramide L were orally administered simultaneously, The amount of ceramide in the blood was evaluated.
  • glucosylceramide GC
  • GC Group Test Solution
  • Y A dose of GC: 1613 mg (100 mg as glucosylceramide, obtained from Nipunceramide RPS, Nippon Flour) was administered per kg of body weight.
  • Z GC + YG group: Test solution (Z): A dose of yogurt (Meiji Bulgaria yogurt fat zero, obtained from Meiji Co., Ltd.): 11.3 g and GC: 1613 mg per kg of body weight was administered.
  • FIG. 13 shows the area under the time curve of the amount of ceramide molecular species in serum. All ceramide molecular species were significantly higher in the GC + YG group in terms of the area under the time curve than in the GC group.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un promoteur d'absorption de sphingolipides qui comprend, comme principe actif, un produit de fermentation et/ou un produit de culture d'une bactérie lactique et/ou d'une bifidobactérie. Selon la présente invention, lors de la prise d'un sphingolipide, l'absorption du sphingolipide peut être améliorée ou favorisée et le sphingolipide peut ainsi être facilement absorbé en toute sécurité et de manière économique (ou efficace).
PCT/JP2016/050071 2015-01-06 2016-01-05 Promoteur d'absorption de sphingolipides WO2016111276A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201680004953.2A CN107106618B (zh) 2015-01-06 2016-01-05 鞘脂吸收促进剂
SG11201704736QA SG11201704736QA (en) 2015-01-06 2016-01-05 Absorption promoter of sphingolipid
JP2016568379A JP6773562B2 (ja) 2015-01-06 2016-01-05 スフィンゴ脂質吸収促進剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-000745 2015-01-06
JP2015000745 2015-01-06

Publications (1)

Publication Number Publication Date
WO2016111276A1 true WO2016111276A1 (fr) 2016-07-14

Family

ID=56355964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/050071 WO2016111276A1 (fr) 2015-01-06 2016-01-05 Promoteur d'absorption de sphingolipides

Country Status (5)

Country Link
JP (1) JP6773562B2 (fr)
CN (1) CN107106618B (fr)
SG (1) SG11201704736QA (fr)
TW (1) TW201630596A (fr)
WO (1) WO2016111276A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017164298A1 (fr) * 2016-03-24 2017-09-28 株式会社 明治 Composition d'inhibition d'érythème, son procédé d'utilisation, son procédé de préparation, procédé d'inhibition d'érythème, et produit de bactéries d'acide lactique
WO2018169027A1 (fr) * 2017-03-16 2018-09-20 株式会社明治 Activateur d'absorption de composé phytochimique
JP2019099528A (ja) * 2017-12-06 2019-06-24 株式会社ユーグレナ スフィンゴ脂質の製造方法、組成物、保湿剤、抗炎症剤及び皮膚バリア機能改善剤
JPWO2020032100A1 (ja) * 2018-08-08 2021-08-10 株式会社明治 フィトケミカル吸収促進用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505201A (ja) * 1996-11-22 2001-04-17 デ・シモーネ，クラウディオ スフィンゴミエリナーゼ組成物およびその使用
JP2012040015A (ja) * 1999-06-09 2012-03-01 Actial Farmaceutica Soc Por Quotas De Responsabilidade Ltda 食養生製品、食品添加物または医薬用アルカリ性スフィンゴミエリナーゼ含有組成物
JP2013181024A (ja) * 2012-03-05 2013-09-12 Snow Brand Milk Products Co Ltd 脂肪酸組成改良剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015110A1 (en) * 2006-12-26 2010-01-21 Meiji Dairies Corporation Fermented milk for skin improvement and/or treatment and process for producing the same
CN101301316B (zh) * 2008-06-26 2011-06-15 福建杨振华851生物科技股份有限公司 一种含乳酸菌发酵物的复方制剂及其制备方法和应用
JP5876214B2 (ja) * 2010-07-15 2016-03-02 康友 荒島 乳酸菌共生培養抽出液の製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505201A (ja) * 1996-11-22 2001-04-17 デ・シモーネ，クラウディオ スフィンゴミエリナーゼ組成物およびその使用
JP2012040015A (ja) * 1999-06-09 2012-03-01 Actial Farmaceutica Soc Por Quotas De Responsabilidade Ltda 食養生製品、食品添加物または医薬用アルカリ性スフィンゴミエリナーゼ含有組成物
JP2013181024A (ja) * 2012-03-05 2013-09-12 Snow Brand Milk Products Co Ltd 脂肪酸組成改良剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANGULO S. ET AL.: "Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase.", PLOS ONE, vol. 6, no. Issue3, 2011, pages 1 - 12 *
FALK P. ET AL.: "Enhancing effects of bile salts on the degradation of glycosphingolipids by glycosidases from bacteria of the human fecal flora.", BIOCHIM. BIOPHYS. ACTA, vol. 1084, no. 2., 1991, pages 139 - 148, XP023578002, DOI: doi:10.1016/0005-2760(91)90212-Z *
HIDEKI FURUYA ET AL.: "Current trend and perspective on the prevention of disease by oral administration of sphingolipids, and utilization of intestinal bacteria to maximize the effect", BULLETIN OF THE FACULTY OF AGRICULTURE, vol. 57, no. 3, 2008, pages 93 - 97 *
KAKUHEI ISAWA ET AL.: "Verifying the Ability of Yogurt Prepared with LB81 Lactic Acid Bacteria to Improve Skin Function", JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 22, no. 1, 2008, pages 1 - 5 *
NESTEL P.J. ET AL.: "Effects of low-fat or full- fat fermented and non-fermented dairy foods on selected cardiovascular biomarkers in overweight adults.", BR. J. NUTR., vol. 110, no. 12, 2013, pages 2242 - 2249 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017164298A1 (fr) * 2016-03-24 2017-09-28 株式会社 明治 Composition d'inhibition d'érythème, son procédé d'utilisation, son procédé de préparation, procédé d'inhibition d'érythème, et produit de bactéries d'acide lactique
WO2018169027A1 (fr) * 2017-03-16 2018-09-20 株式会社明治 Activateur d'absorption de composé phytochimique
JPWO2018169027A1 (ja) * 2017-03-16 2020-01-16 株式会社明治 フィトケミカル吸収促進剤
JP7177039B2 (ja) 2017-03-16 2022-11-22 株式会社明治 フィトケミカル吸収促進剤
JP2019099528A (ja) * 2017-12-06 2019-06-24 株式会社ユーグレナ スフィンゴ脂質の製造方法、組成物、保湿剤、抗炎症剤及び皮膚バリア機能改善剤
JP7001450B2 (ja) 2017-12-06 2022-01-19 株式会社ユーグレナ 組成物及び抗炎症剤
JPWO2020032100A1 (ja) * 2018-08-08 2021-08-10 株式会社明治 フィトケミカル吸収促進用組成物
JP7385572B2 (ja) 2018-08-08 2023-11-22 株式会社明治 フィトケミカル吸収促進用組成物

Also Published As

Publication number Publication date
CN107106618B (zh) 2021-09-07
JPWO2016111276A1 (ja) 2017-10-12
TW201630596A (zh) 2016-09-01
SG11201704736QA (en) 2017-07-28
CN107106618A (zh) 2017-08-29
JP6773562B2 (ja) 2020-10-21

Similar Documents

Publication Publication Date Title
JP5923238B2 (ja) 迷走神経活性化剤
JP6234227B2 (ja) 腸内菌叢改善用栄養組成物
JP5581071B2 (ja) ミトコンドリア機能向上剤
WO2015013932A1 (fr) Composition nutritionnelle pour inhiber la croissance d'une tumeur
JP6773562B2 (ja) スフィンゴ脂質吸収促進剤
NL2002768C2 (en) Satiety inducing milk product.
TW202015535A (zh) 極性脂質於治療或預防妊娠糖尿病之應用
WO2011071134A1 (fr) Composition prophylactique pour infection grippale
Perotti et al. Production of functional milk-based beverages
WO2016021573A1 (fr) Agent permettant de favoriser la production de céramide lié de manière covalente à une cellule cornée
JPWO2018186425A1 (ja) 血中アミノ酸濃度上昇促進用発酵乳
JP6037595B2 (ja) 満腹感誘導組成物及びその製造方法
JP5950993B2 (ja) 迷走神経活性化剤
CN109475583B (zh) 用于抑制红斑产生的组合物及其使用方法和制造方法、抑制红斑产生的方法、乳酸菌产物
AU2017287987A1 (en) Cartilage regeneration facilitating composition
JP7383874B2 (ja) エンドトキシンの血中移行阻害用組成物
JP2021107400A (ja) 肥満抑制剤
JP6849890B2 (ja) デオキシリボ核酸保存用組成物およびその製造方法、デオキシリボ核酸を保存する方法、乳酸菌産生物およびその使用方法
Madureira et al. Functional dairy ingredients
Malik et al. Health benefits of ethnic Indian milk products
WO2016104665A1 (fr) Agent pour inhiber ou améliorer la diminution de loricrine, activateur de transglutaminase-3, et agent pour favoriser la formation d'enveloppe cornée de couche de cellule morte de peau ou pour renforcer la structure d'enveloppe cornée de couche de cellule morte de peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16735015

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016568379

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11201704736Q

Country of ref document: SG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16735015

Country of ref document: EP

Kind code of ref document: A1